HealthInvest Partners AB Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)

HealthInvest Partners AB bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 15,432 shares of the company’s stock, valued at approximately $360,000.

A number of other hedge funds have also modified their holdings of the business. Strs Ohio grew its holdings in shares of Akero Therapeutics by 100.0% during the 4th quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $46,000 after purchasing an additional 1,000 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Akero Therapeutics by 31.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,885 shares of the company’s stock worth $931,000 after purchasing an additional 9,567 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Akero Therapeutics by 352.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,449 shares of the company’s stock worth $151,000 after purchasing an additional 5,023 shares during the period. Vanguard Group Inc. grew its holdings in shares of Akero Therapeutics by 12.1% during the 3rd quarter. Vanguard Group Inc. now owns 3,012,182 shares of the company’s stock worth $152,356,000 after purchasing an additional 326,308 shares during the period. Finally, Orion Capital Management LLC purchased a new position in shares of Akero Therapeutics during the 3rd quarter worth $51,000.

Insider Transactions at Akero Therapeutics

In other news, CEO Andrew Cheng sold 75,000 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.87, for a total transaction of $2,465,250.00. Following the sale, the chief executive officer now owns 591,416 shares of the company’s stock, valued at approximately $19,439,843.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Akero Therapeutics news, CEO Andrew Cheng sold 75,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $32.87, for a total transaction of $2,465,250.00. Following the transaction, the chief executive officer now owns 591,416 shares of the company’s stock, valued at $19,439,843.92. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $24.38, for a total value of $121,900.00. Following the transaction, the chief operating officer now directly owns 263,306 shares in the company, valued at approximately $6,419,400.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 100,646 shares of company stock valued at $3,319,877. Corporate insiders own 9.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on AKRO shares. UBS Group increased their price target on Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. HC Wainwright raised their target price on Akero Therapeutics from $40.00 to $43.00 and gave the company a “buy” rating in a report on Friday, March 1st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $39.00.

Akero Therapeutics Trading Up 0.3 %

Akero Therapeutics stock traded up $0.07 during midday trading on Tuesday, reaching $21.79. 940,162 shares of the stock traded hands, compared to its average volume of 1,295,313. The company has a 50-day simple moving average of $24.56 and a two-hundred day simple moving average of $22.12. The company has a current ratio of 29.27, a quick ratio of 29.27 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.23 billion, a PE ratio of -7.65 and a beta of -0.38. Akero Therapeutics, Inc. has a 12-month low of $11.25 and a 12-month high of $58.38.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.17). Research analysts expect that Akero Therapeutics, Inc. will post -4.06 earnings per share for the current fiscal year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.